Protagonist Therapeutics (PTGX) Assets Average (2016 - 2026)
Protagonist Therapeutics (PTGX) posted Assets Average of $682.8 million for Q1 2026, little changed sequentially from $684.9 million in Q4 2025, and down 8.15% YoY from $743.4 million in Q1 2025.
Protagonist Therapeutics (PTGX) Assets Average (2016 - 2026) Analysis & Trends
Protagonist Therapeutics has reported Assets Average for 11 years, with the latest figure at $682.8 million in Q1 2026.
- Quarterly Assets Average fell 8.15% year-over-year to $682.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $682.8 million (down 8.15% YoY) and the FY2025 annual result came in at $706.5 million, up 28.13% from the prior year.
- Assets Average steadied at $682.8 million in Q1 2026 per PTGX's latest filing, from $684.9 million in the prior quarter.
- Over five years, Assets Average peaked at $743.4 million in Q1 2025 and troughed at $243.9 million in Q1 2023.
- A 5-year average of $493.1 million and a median of $493.6 million in 2024 frame the typical range for Assets Average.
- The sharpest annual moves came in 2023 and 2024: Assets Average fell 29.91% in 2023, then surged 122.0% in 2024.
- Over 5 years, Assets Average stood at $265.1 million in 2022, then rose by 29.78% to $344.0 million in 2023, then surged by 96.02% to $674.3 million in 2024, then gained by 1.58% to $684.9 million in 2025, then fell by 0.31% to $682.8 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $682.8 million, $684.9 million, and $709.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Protagonist Therapeutics | 10.03 Bn | 10.03 Bn | - | 791.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 791.50 Mn |
| Mar 31, 2026 | 682.82 Mn |
| Dec 31, 2025 | 684.94 Mn |
| Sep 30, 2025 | 709.85 Mn |
| Jun 30, 2025 | 730.07 Mn |
| Mar 31, 2025 | 743.43 Mn |
| Dec 31, 2024 | 674.29 Mn |
| Sep 30, 2024 | 609.24 Mn |
| Jun 30, 2024 | 621.95 Mn |
| Mar 31, 2024 | 493.61 Mn |
| Dec 31, 2023 | 343.98 Mn |
| Sep 30, 2023 | 325.24 Mn |
| Jun 30, 2023 | 280.16 Mn |
| Mar 31, 2023 | 243.89 Mn |
| Dec 31, 2022 | 265.05 Mn |
| Sep 30, 2022 | 296.34 Mn |
| Jun 30, 2022 | 329.40 Mn |
| Mar 31, 2022 | 348.00 Mn |
| Dec 31, 2021 | 360.44 Mn |
| Sep 30, 2021 | 388.70 Mn |